nach oben

Endocrine

Erschienen in:

17.05.2019 | Original Article

Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells

verfasst von: Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung-Hee Ihm, Moon Gi Choi, Seong Jin Lee

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of evodiamine in combination with histone deacetylase (HDAC) inhibitors on survival of thyroid carcinoma cells was identified.

Methods

TPC-1 and SW1736 human thyroid carcinoma cells were used.

Results

After treatment with evodiamine and PXD101, cell viability, the percentage of viable cells and Bcl2 protein levels decreased, whereas cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX, acetyl. histone H3 and cleaved PARP, and reactive oxygen species (ROS) production increased. In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of γH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio. Furthermore, all of the combination index values were <1.0, suggesting synergistic cytotoxicity of two agents. Wortmannin decreased cell viability and the percentage of viable cells, whereas it increased cytotoxic activity and the percentage of apoptotic cells without alteration in ROS production. The changes in cells treated with both evodiamine and suberoylanilide hydroxamic acid or trichostatin A were similar to those in cells treated with both evodiamine and PXD101.

Conclusions

Our results demonstrate that evodiamine synergizes with HDAC inhibitors in inducing cytotoxic activities by involving survival-related proteins and ROS in thyroid carcinoma cells. Moreover, repression of PI3K/Akt signaling synergistically reinforces cytotoxicity of evodiamine combined with HDAC inhibitors in thyroid carcinoma cells.

Nur mit Berechtigung zugänglich

M. Molina-Vega, J. García-Alemán, A. Sebastián-Ochoa, I. Mancha-Doblas, J.M. Trigo-Pérez, F. Tinahones-Madueño, Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine 59, 395–401 (2018)CrossRefPubMed

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentral

R.C. Smallridge, K.B. Ain, S.L. Asa, K.C. Bible, J.D. Brierley, K.D. Burman, E. Kebebew, N.Y. Lee, Y.E. Nikiforov, M.S. Rosenthal, M.H. Shah, A.R. Shaha, R.M. Tuttle, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104–1139 (2012)CrossRefPubMed

H. Yu, H. Jin, W. Gong, Z. Wang, H. Liang, Pharmacological actions of multi-target-directed evodiamine. Molecules 18, 1826–1843 (2013)CrossRefPubMedPubMedCentral

J. Jiang, C. Hu, Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 14, 1852–1859 (2009)CrossRefPubMedPubMedCentral

Y. Takada, Y. Kobayashi, B.B. Aggarwal, Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 280, 17203–17212 (2005)CrossRefPubMed

C. Wang, S. Li, M.W. Wang, Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol. In Vitro 24, 898–904 (2010)CrossRefPubMed

F. Yang, L. Shi, T. Liang, L. Ji, G. Zhang, Y. Shen, F. Zhu, L. Xu, Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 485, 54–61 (2017)CrossRefPubMed

M.C. Chen, C.H. Yu, S.W. Wang, H.F. Pu, S.F. Kan, L.C. Lin, C.W. Chi, L.L. Ho, C.H. Lee, P.S. Wang, Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J. Cell. Biochem. 110, 1495–1503 (2010)CrossRefPubMed

10.

C.C. Chien, M.S. Wu, S.C. Shen, C.H. Ko, C.H. Chen, L.L. Yang, Y.C. Chen, Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine. PLoS ONE 9, e99729 (2014)CrossRefPubMedPubMedCentral

11.

C. Fang, J. Zhang, D. Qi, X. Fan, J. Luo, L. Liu, Q. Tan, Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells. PLoS ONE 9, e115204 (2014)CrossRefPubMedPubMedCentral

12.

L. Lin, L. Ren, L. Wen, Y. Wang, J. Qi, Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells. Mol. Med. Rep. 14, 2832–2838 (2016)CrossRefPubMed

13.

Z.J. Meng, N. Wu, Y. Liu, K.J. Shu, X. Zou, R.X. Zhang, C.J. Pi, B.C. He, Z.Y. Ke, L. Chen, Z.L. Deng, L.J. Yin, Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling. Oncol. Rep. 34, 1388–1396 (2015)CrossRefPubMed

14.

W.T. Wei, H. Chen, Z.H. Wang, Z.L. Ni, H.B. Liu, H.F. Tong, H.C. Guo, D.L. Liu, S.Z. Lin, Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int. J. Biol. Sci. 8, 1–14 (2012)CrossRefPubMed

15.

S. Wang, L. Wang, Z. Shi, Z. Zhong, M. Chen, Y. Wang, Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS ONE 9, e97512 (2014)CrossRefPubMedPubMedCentral

16.

C.H. Liao, S.L. Pan, J.H. Guh, Y.L. Chang, H.C. Pai, C.H. Lin, C.M. Teng, Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26, 968–975 (2005)CrossRefPubMed

17.

Z.F. Zhong, W. Tan, S.P. Wang, W.A. Qiang, Y.T. Wang, Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. Sci. Rep. 5, 16415 (2015)CrossRefPubMedPubMedCentral

18.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, S.J. Lee, Evodiamine suppresses survival, proliferation, migration and epithelial-mesenchymal transition of thyroid carcinoma cells. Anticancer Res. 38, 6339–6352 (2018)CrossRefPubMed

19.

P.A. Marks, M. Dokmanovic, Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511 (2005)CrossRefPubMed

20.

C. Robert, F.V. Rassool, HDAC inhibitors: roles of DNA damage and repair. Adv. Cancer Res. 116, 87–129 (2012)CrossRefPubMed

21.

S.F. Lin, J.D. Lin, T.C. Chou, Y.Y. Huang, R.J. Wong, Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS ONE 8, e77684 (2013)CrossRefPubMedPubMedCentral

22.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 100, E253–E261 (2015)CrossRefPubMed

23.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine 51, 274–282 (2016)CrossRefPubMed

24.

Q.T. Luong, J. O’Kelly, G.D. Braunstein, J.M. Hershman, H.P. Koeffler, Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 12, 5570–5577 (2006)CrossRefPubMed

25.

I. Clinckspoor, L. Verlinden, L. Overbergh, C. Korch, R. Bouillon, C. Mathieu, A. Verstuyf, B. Decallonne, 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. J. Steroid Biochem. Mol. Biol. 124, 1–9 (2011)CrossRefPubMed

26.

R. Zarnegar, L. Brunaud, H. Kanauchi, M. Wong, M. Fung, D. Ginzinger, Q.Y. Duh, O.H. Clark, Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor. Surgery 132, 984–990 (2002)CrossRefPubMed

27.

S. He, G. Dong, Z. Wang, W. Chen, Y. Huang, Z. Li, Y. Jiang, N. Liu, J. Yao, Z. Miao, W. Zhang, C. Sheng, Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors. ACS Med. Chem. Lett. 6, 239–243 (2015)CrossRefPubMedPubMedCentral

28.

Y.L. Li, N.Y. Zhang, X. Hu, J.L. Chen, M.J. Rao, L.W. Wu, Q.Y. Li, B. Zhang, W. Yan, C. Zhang, Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1α under hypoxia. Biochem. Biophys. Res. Commun. 498, 481–486 (2018)CrossRefPubMed

29.

M. Xing, Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20, 697–706 (2010)CrossRefPubMedPubMedCentral

30.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells. Anticancer Res. 34, 4829–4837 (2014)PubMed

31.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Endocrine 48, 886–893 (2015)CrossRefPubMed

32.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells. Biomed. Pharmacother. 83, 22–32 (2016)CrossRefPubMed

33.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. Endocrine 59, 383–394 (2018)CrossRefPubMed

34.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells. J. Endocrinol. Invest. 41, 677–689 (2018)CrossRefPubMed

35.

Y.J. Kim, H.-J. Hwang, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, S.J. Lee, Enigma plays roles in survival of thyroid carcinoma cells through PI3K/AKT signaling and survivin. Anticancer Res. 38, 3515–3525 (2018)CrossRefPubMed

36.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAF^V600E. J. Endocrinol. Invest. 36, 1099–1104 (2013)PubMed

37.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm. Metab. Res. 45, 408–414 (2013)CrossRefPubMed

38.

S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in anaplastic thyroid carcinoma cells. Anticancer Res. 35, 6529–6537 (2015)PubMed

39.

S. Cory, J.M. Adams, The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647–656 (2002)CrossRefPubMed

40.

S. Cory, J.M. Adams, Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8, 5–6 (2005)CrossRefPubMed

41.

R.E. Schweppe, J.P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J.A. Knauf, J.A. Fagin, L.A. Marlow, J.A. Copland, R.C. Smallridge, B.R. Haugen, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331–4341 (2008)CrossRefPubMedPubMedCentral

42.

Z. Lv, D. Zhao, R. Liu, J. Guo, Y. Lin, M. Zhang, Evodiamine inhibits proliferation of human papillary thyroid cancer cell line K1 by regulating of PI3K/Akt signaling pathway. Int. J. Clin. Exp. Med. 9, 15216–15225 (2016)

43.

J.R. Testa, P.N. Tsichlis, AKT signaling in normal and malignant cells. Oncogene 24, 7391–7393 (2005)CrossRefPubMed

Titel: Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells
verfasst von: Si Hyoung Kim
Jun Goo Kang
Chul Sik Kim
Sung-Hee Ihm
Moon Gi Choi
Seong Jin Lee
Publikationsdatum: 17.05.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01885-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Bone turnover is altered during 72 h of sleep restriction: a controlled laboratory study

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials

Adrenocortical carcinoma: presentation and outcome of a contemporary patient series

Comparison of stress response following microwave ablation and surgical resection of benign thyroid nodules

Premature death and risk of cardiovascular disease in young-onset diabetes: a 23-year follow-up of the Da Qing Diabetes Study

Decreased deiodinase activity after glucose load could lead to atherosclerosis in euthyroid women with polycystic ovary syndrome

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin